greeksoup/ stock research
Stock research / United States / PFE · Pharmaceutical Preparations · NYSE

Pfizer Inc. (PFE)

Pfizer is a research-based global biopharmaceutical company, discovering, developing, manufacturing, marketing, selling and distributing biopharmaceutical products worldwide. It was incorporated in Delaware on 2 June 1942. Most of what it earns comes from making and selling those products. At the end of 2025 it employed approximately 75,000 people worldwide.

Pfizer Inc.

Pfizer is a research-based global biopharmaceutical company, discovering, developing, manufacturing, marketing, selling and distributing biopharmaceutical products worldwide. It was incorporated in Delaware on 2 June 1942. Most of what it earns comes from making and selling those products. At the end of 2025 it employed approximately 75,000 people worldwide.

Commercial operations run through three operating segments. Biopharma is the science-based medicines business and is the only reportable segment. PC1 is the contract development and manufacturing organisation and a supplier of specialty active pharmaceutical ingredients. Pfizer Ignite provided strategic advice and end-to-end research and development services to selected biotech companies; during 2025 Pfizer decided to discontinue it and is winding it down while transitioning the work with its partners.

How the selling is organised

Inside Biopharma, commercial divisions market, sell and distribute the products while global operating functions handle research, development, manufacturing and supply. Through 2025 there were two divisions: Pfizer U.S. Commercial, covering the whole portfolio in the United States, and Pfizer International Commercial, covering it everywhere else. Effective 1 January 2026 a third was created. Global Hospital and Biosimilars took the off-patent branded and generic sterile injectables and biosimilars out of the Specialty Care and Oncology portfolios, covering them everywhere except China, Hong Kong and certain other international markets.

What it sells

Primary Care holds the internal medicine portfolio in cardiovascular metabolic diseases, including Eliquis and brands that have already passed patent expiry or lost regulatory exclusivity; the migraine products Nurtec ODT, sold as Vydura in some markets, and Zavzpret; the vaccines portfolio across all ages, including the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba; and Paxlovid for COVID-19.

Specialty Care holds inflammation and immunology, including Xeljanz, Enbrel outside the United States and Canada, Cibinqo, Litfulo, Eucrisa and Velsipity; rare disease across amyloidosis, hemophilia and endocrine diseases, including the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi; and certain anti-infective and immunoglobulin medicines, including Zavicefta outside the United States and Canada, Octagam and Panzyga.

Oncology covers antibody-drug conjugates, small molecules, bispecifics and other immunotherapies across breast, genitourinary, hematologic, melanoma, gastrointestinal, gynecological and lung cancers, with Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna among the named products.

Hospital and Biosimilars covers off-patent branded and generic sterile injectables together with oncology biosimilars and biosimilars for chronic immune and inflammatory diseases. Named products include the biosimilar Inflectra, the oncology biosimilars Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and the sterile injectables Sulperazon outside the United States and Canada, Atgam, Fragmin, Solu Medrol, Solu Cortef and Bicillin.

How a product reaches a patient

Prescription products are sold principally to wholesalers, and also directly to retailers, hospitals, clinics, government agencies and pharmacies. Vaccines follow a different route: in the United States they go primarily direct to the federal government, including the CDC, and to wholesalers, individual provider offices, retail pharmacies and integrated delivery systems, while outside the United States they go primarily to government and non-government institutions, under contracts a government entity may renegotiate or terminate at its discretion.

Beyond the sale itself the work is getting on a formulary, the list of approved medicines available to members of a healthcare programme or a pharmacy benefit manager. Insurers and the benefit managers who negotiate on their behalf use devices such as tiered co-payments to push volume towards preferred positions, typically in exchange for a discount off the price in the form of a rebate agreement. The company promotes to healthcare providers and, in the United States, to managed care organisations, hospitals, integrated delivery systems, benefit managers, health plans, employers and government agencies. It advertises directly to consumers in the United States and selected international markets, and sponsors general advertising on disease awareness and prevention. Under a voluntary agreement with the United States government it also participates in the TrumpRx.gov platform, which lets patients there buy certain medicines at discounts to current retail prices.

From Pfizer's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Pfizer became

Latest results

Latest quarterQ3 FY2026ended 27 September 2026 · 10-Q filed 3 November 2026
Revenue
$16.6 billion
-0.4% on the year · +10.3% on the quarter
Q4 FY2024Q3 FY2026
Net income
$3.2 billion
-8.4% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$0.56
-9.7% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 26 February 2026
Revenue
$62.6 billion
-1.6% on the year
FY2018FY2025
Net income
$7.8 billion
-3.2% on the year
FY2018FY2025
Diluted EPS
$1.36
-3.5% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsPfizer (PFE) reported revenue of $62.6 billion for fiscal 2025, the year ended 31 December 2025, down 1.6% on the year before. Net income was $7.8 billion and diluted earnings per share $1.36. Revenue was $63.6 billion in fiscal 2024, $59.6 billion in fiscal 2023, $101.2 billion in fiscal 2022 and $81.3 billion in fiscal 2021. Net income in the same years was $8.0 billion, $2.1 billion, $31.4 billion and $22.0 billion. Over the twelve months to 27 September 2026, Pfizer reported revenue of $63.6 billion and net income of $4.0 billion. Revenue grew 8.5% a year, compounded, over the five years to fiscal 2025. Pfizer declared $1.72 a share in dividends over the last four quarters and had 5.70 billion shares outstanding at the latest filed count. At 27 September 2026 it carried $62.6 billion of debt and $1.8 billion of cash. At the close of 6 November 2026 the market cap of Pfizer was $167.5 billion, 42.0 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE4.5%
ROCEn/a
Operating marginn/a
Net margin6.3%
FCF margin18.5%
Interest covern/a
Debt to equity0.70x
Cash conversion3.51x
Share count, last 12 months0.2%
Sales CAGR, 3 years-14.8%
Profit CAGR, 3 years-37.2%
EPS, TTM$0.70

At the close of 6 November 2026

Price$29.39
Market cap$167.5 billion
Stock P/E42.0x
Price to book1.9x
EV / EBITDAn/a
Dividend yield5.9%
Market cap / sales2.6x
52-week high$30.79
52-week low$23.67
Price, 1 year18.2%
Price CAGR, 3 years-2.0%
Price CAGR, 5 years-9.6%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Pfizer Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
PFEgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue23,63525,66127,74222,63824,28918,48613,00713,49114,24814,87913,28317,70217,76313,71514,65316,65417,55714,45115,03416,583
Cost of revenue9,7369,9848,6486,0639,6494,8863,2379,2697,5623,3793,3005,2635,9092,8453,7784,1725,2723,5484,0924,028
Gross profit13,89915,67719,09416,57514,64013,6009,7704,2226,68611,5009,98312,43911,85410,87010,87512,48212,28510,90310,94212,555
Gross margin59%61%69%73%60%74%75%31%47%77%75%70%67%79%74%75%70%75%73%76%
R&D5,9092,3012,8152,6963,6162,5052,6482,7112,8152,4932,6962,5983,0352,2032,4822,5463,2062,4902,8093,016
SG&A4,0992,5933,0483,3914,6453,4183,4973,2814,5753,4953,7173,2444,2743,0313,4153,1864,1622,9613,4113,279
Interest expense314322293311312318508695688790778783740654654652711668667662
Pre-tax income3,8439,05011,4479,0015,2316,2702,269-3,352-4,1293,421-1034,715-10.02,7853,0443,334-1,6433,170-6533,385
Tax rate6%13%14%4%4%11%-3%n/an/a9%n/a5%n/a-7%5%-6%n/a15%n/a4%
Net income3,3937,8649,9068,6084,9945,5432,327-2,382-3,3693,11541.04,4654102,9672,9103,541-1,6472,687-2483,242
Net margin14%31%36%38%21%30%18%-18%-24%21%0%25%2%22%20%21%-9%19%-2%20%
Diluted EPS$0.59$1.37$1.73$1.51$0.87$0.97$0.41-$0.42-$0.60$0.55$0.01$0.78$0.07$0.52$0.51$0.62-$0.29$0.47-$0.04$0.56
Operating cash flow5,9146,5418,1705,9748,5821,212-1,2083,4565,2401,090-1,7816,7146,7212,335-5824,6035,3482,6158355,375
Capital expenditure9936437518411,0011,1399148101,044704637651917564618602845436533573
Free cash flow4,9215,8987,4195,1337,58173.0-2,1222,6464,196386-2,4186,0635,8041,771-1,2004,0014,5032,1793024,802
Buybacks0.02,0000.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid2,1892,2492,2442,2452,2452,3032,3152,3142,3152,3722,3802,3802,3802,4372,4452,4442,4452,4452,4512,451
Shares outstanding5,619m5,645m5,646m5,646m5,619m5,645m5,646m5,646m5,647m5,667m5,667m5,667m5,667m5,685m5,686m5,686m5,686m5,699m5,700m5,700m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Revenue48,41848,29649,26965,16561,03554,65751,58449,60548,85152,82452,54640,82540,90541,65181,288101,17559,55363,62762,57963,625
Cost of revenue11,2398,1128,45914,78812,5009,8219,5869,5779,64812,32211,2288,9878,0548,48430,82134,34424,95417,85116,06716,940
Gross profit37,17940,18440,81050,37748,53544,83641,99840,02839,20340,50241,31831,83832,85133,16750,46766,83134,59945,77646,51246,685
Gross margin76.8%83.2%82.8%77.3%79.5%82.0%81.4%80.7%80.3%76.7%78.6%78.0%80.3%79.6%62.1%66.1%58.1%71.9%74.3%73.4%
Research and development8,0897,9457,8249,4838,6817,4826,6788,3937,6907,8927,6837,7608,3858,70910,36011,42810,67910,82210,43711,521
Selling, general and administrative15,62614,53714,75218,97317,58115,17114,35514,09714,80914,83714,78412,61212,72611,61512,70313,67714,77114,73013,79413,813
Interest expensen/a5161,2331,7991,6811,5241,4141,3601,1991,1861,2701,3161,5741,4491,2911,2382,2093,0912,6712,708
Pre-tax income9,2789,69410,6749,47111,48111,24215,71612,2408,9658,35112,3053,59411,3217,03624,31134,7291,0588,0237,5204,259
Income tax1,0231,6452,1451,1533,6212,2214,3063,1201,9901,123-9,049-2665833701,8523,328-1,115-28.0-266186
Effective tax rate11.0%17.0%20.1%12.2%31.5%19.8%27.4%25.5%22.2%13.4%-73.5%-7.4%5.1%5.3%7.6%9.6%-105.4%-0.3%-3.5%4.4%
Net income8,1448,1048,6358,25710,00914,57022,0039,1356,9607,21521,30811,15316,0269,15921,97931,3722,1198,0317,7714,034
Net margin16.8%16.8%17.5%12.7%16.4%26.7%42.7%18.4%14.2%13.7%40.6%27.3%39.2%22.0%27.0%31.0%3.6%12.6%12.4%6.3%
Diluted EPS$1.17$1.20$1.23$1.02$1.27$1.94$3.19$1.42$1.11$1.17$3.52$1.87$2.82$1.63$3.85$5.47$0.37$1.41$1.36$0.70
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2009 to FY2025, 2 years left out

FY2009FY2010FY2011FY2012FY2013FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States21,54028,85525,27721,31320,27426,36926,02620,11920,32621,45529,74643,31728,14538,69137,07859.2%
Developed Marketsn/an/an/an/an/an/an/an/an/an/an/a40,53420,91016,05716,18825.9%
Emerging Markets7,04610,26310,11510,84311,22510,42011,3998,6188,8288,37220,70117,32410,4988,8799,31314.9%
Developed Europe12,58616,15615,22112,54511,7399,3068,5087,9977,7297,78818,336n/an/an/an/an/a
Developed Rest of World8,0979,89110,4229,9568,3466,7296,6124,0904,0224,03612,506n/an/an/an/an/a
United StatesDeveloped Markets FY2022 to FY2025Emerging MarketsDeveloped Europe FY2009 to FY2021Developed Rest of World FY2009 to FY2021
49.3FY200961.0FY201151.6FY201352.5FY201740.9FY201981.3FY202159.6FY202362.6FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Pfizer's adjusted EPS landed at or above the top of the range in 2 and under it in 1 of the 3 years shown (FY2022 to FY2024).

+0.5%FY2022−46.7%FY2023+38.2%FY2024
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2022$6.35 to $6.55$6.58
FY2023$3.25 to $3.45$1.84
FY2024$2.05 to $2.25$3.11
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Operating cash flow13,35318,23816,58711,45420,24016,74617,68417,08414,68816,19216,80215,82712,58814,40332,58029,2678,70012,74411,70414,173
Capital expenditure1,8801,7011,2051,5131,6601,3271,2061,1991,3971,8231,9561,9842,0462,2262,7113,2363,9072,9092,6292,387
Free cash flow11,47316,53715,3829,94118,58015,41916,47815,88513,29114,36914,84613,84310,54212,17729,86926,0314,7939,8359,07511,786
Free cash flow margin23.7%34.2%31.2%15.3%30.4%28.2%31.9%32.0%27.2%27.2%28.3%33.9%25.8%29.2%36.7%25.7%8.0%15.5%14.5%18.5%
Cash from investing795-12,835-31,272-4921,8436,154-10,544-5,654-2,980-7,791-4,7414,525-3,945-4,271-22,546-15,783-32,2782,652-1,351-5,281
Cash from financing-12,610-6,56014,481-11,174-20,607-15,999-14,975-10,187-10,409-9,228-13,350-20,441-8,485-9,649-9,816-14,83426,066-17,140-10,304-8,429
Depreciation and amortisation5,2005,0904,7578,3998,7017,3946,3065,5375,1575,7576,2696,3845,7554,6815,1915,0646,2907,0136,5926,499
Share-based compensation4373843494054194815235866696918409236877561,1828725258777991,108
Buybacks9,9945000.01,0009,0008,22816,2905,0006,1605,0005,00012,1988,8650.00.02,0000.00.0n/an/a
Dividends paid7,9758,5415,5486,0886,2346,5346,5806,6096,9407,3177,6597,9788,0438,4408,7298,9839,2479,5129,7719,792
Dividend per sharen/an/an/a$0.72$0.80$0.88$0.96$1.04$1.12$1.22$1.30$1.38$1.46$1.53$1.57$1.61$1.65$1.69$1.72n/a
Diluted shares, weighted6,939m6,750m7,045m8,074m7,870m7,508m6,895m6,424m6,257m6,159m6,058m5,977m5,675m5,632m5,708m5,733m5,709m5,700m5,713m5,751m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a5,700m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023 †FY2024FY2025TTM
Funded by
Shareholders' equity65,12457,55690,01487,81382,19081,26076,30771,30164,72059,54471,30863,40763,14363,23877,20195,66189,01488,20386,47689,001
Non-controlling interestn/a184432452431418313321278296348351303235262256274294299299
Debtn/a8,90043,22044,01338,94237,46036,48936,68238,89942,08643,49141,74052,15039,83638,43635,82971,88864,35164,63862,601
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a1,0301,1082,5102,5972,6262,2862,291n/a
Other liabilitiesn/a44,50879,28362,73666,43966,66058,99259,26263,56369,68956,65053,92450,86349,81263,06762,86262,69958,26254,45652,643
Total liabilities and equityn/a111,148212,949195,014188,002185,798172,101167,566167,460171,615171,797159,422167,489154,229181,476197,205226,501213,396208,160204,544
Owned
Fixed assetsn/a13,28722,78017,60714,67313,21312,39711,76213,76613,31813,86513,38512,96913,74514,88216,27418,94018,39319,31719,048
Goodwilln/a21,46442,37643,43244,56943,66142,51942,06948,24254,44955,95242,92748,18149,57749,20851,37567,78368,52771,26471,464
Intangible assetsn/a17,72168,01557,55851,18445,14639,38535,16640,35652,64848,74135,21133,93628,33725,14643,37064,90055,41153,73145,956
Investmentsn/a21,60923,99126,27733,08436,46846,63150,29735,64822,37125,66520,28028,67230,69943,54033,81219,76813,1099,1849,118
Cash and equivalents3,4062,1221,9781,7353,18210,0812,1833,3433,6412,5951,3421,1391,1211,7841,9444162,8531,0431,1421,824
Receivablesn/a8,95814,64513,38013,05810,6759,3578,4018,1768,2258,2218,0256,7727,91311,47910,95211,56611,46311,87414,192
Inventoryn/a4,38112,4038,2756,6106,0766,1665,6637,5136,7837,5787,5087,0688,0209,0598,98110,18910,85110,65410,022
Other assetsn/a21,60626,76126,75021,64220,47813,46310,86510,11811,22610,43330,94728,77014,15426,21832,02530,50234,59930,99432,920
Total assetsn/a111,148212,949195,014188,002185,798172,101167,566167,460171,615171,797159,422167,489154,229181,476197,205226,501213,396208,160204,544
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded2.5%8.5%-14.8%1.3%
Profit growth, compounded1.1%-3.2%-37.2%-59.0%
Return on equity, average18.1%16.3%6.8%9.0%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Pfizer's revenue in fiscal 2025?

Pfizer (PFE) reported revenue of $62.6 billion for fiscal 2025, the year ended 31 December 2025, down 1.6% on the year before.

How much did Pfizer earn in fiscal 2025?

Net income was $7.8 billion for fiscal 2025, and diluted earnings per share $1.36.

What is Pfizer's P/E ratio?

At the close of 6 November 2026, Pfizer traded at 42.0 times its earnings over the twelve months to 27 September 2026.

What is Pfizer's market cap?

The market cap of Pfizer was $167.5 billion at the close of 6 November 2026.

Does Pfizer pay a dividend?

Yes. Pfizer declared $1.72 a share in dividends over the four quarters to 27 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on PFE

Dividends$1.72 a share over the four quarters to 27 September 2026, a 5.85% yield
Filings21 in twelve months: 11 current reports (8-K), about 4 results of operations; 2 officer or director change; 2 regulation FD disclosure; 2 other events; 1 shareholder vote
Planned insider salesno Form 144 notice in twelve months
Options tapeput/call 0.98 by open interest at the 6 November 2026 close; the straddle prices a 3.1% move to 13 November 2026
13F holders2,854 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading2 sales and 3 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest137.8 million shares short, 4.47 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q27 September 20263 November 2026EDGAR
10-Q28 June 20264 August 2026EDGAR
10-Q29 March 20265 May 2026EDGAR
10-K31 December 202526 February 2026EDGAR
10-Q28 September 20254 November 2025EDGAR
10-Q29 June 20255 August 2025EDGAR
10-Q30 March 20255 May 2025EDGAR
10-K31 December 202427 February 2025EDGAR
10-Q29 September 20244 November 2024EDGAR
10-Q30 June 20245 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.